In 2012, the three largest competitors in the market for diabetes diagnosis, treatment and drug delivery competed exclusively in the insulin and insulin pen markets.
Competition within the total diabetes market was extremely segmented based on market area. Companies with leading shares in the insulin segments also held strong shares in the overall market. These companies include Novo Nordisk, Sanofi and Eli Lilly. To read more about the European Diabetes Monitoring, Treatment, and Drug Delivery Market you can request a free report synopsis by clicking here.
Meanwhile, the traditional blood glucose meter, test strip, lancet and lancing device markets were dominated by several different companies, which have established their shares by offering a large product range and maintaining customer satisfaction in a lucrative marketplace.
Brand recognition allows these large companies to gain the trust of both diabetic patients and their physicians with the knowledge that their glucose monitoring products will provide an accurate and reliable reading to maintain glucose homeostasis.